On October 19, 2026 PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, reported that results from the completed Phase 1b clinical trial of LYT-200 will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23–27 in Madrid, Spain. LYT-200 is a first-in-class monoclonal antibody targeting galectin-9, an important oncogenic driver and potent immunosuppressor, being advanced by PureTech’s Founded Entity, Gallop Oncology (Gallop).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The Phase 1b results provide a strong foundation for the continued development of LYT-200, particularly in relapsed/refractory high-risk MDS, where patients have extremely limited treatment options," said Aleksandra Filipovic, MD, PhD, Head of Oncology at PureTech and Chief Medical Officer of Gallop Oncology. "The encouraging clinical activity observed, together with the favorable safety profile, reinforces our confidence in the potential of LYT-200 to offer a differentiated treatment approach for a broad population of patients, regardless of mutation status. We look forward to sharing these findings with the oncology community in an oral presentation at ESMO (Free ESMO Whitepaper) as we prepare to advance LYT-200 into Phase 2 development."
Details of the presentation are as follows:
Title: Topline Results from a Phase 1b Study of LYT-200 (Anti-Galectin-9 mAb) Alone and with HMA ± Venetoclax in Relapsed/Refractory High-Risk MDS and AML
Presenter: Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Baptist Health Herbert Wertheim Cancer Institute
Session: Proffered Paper: Hematological Malignancies (located at Salamanca Auditorium – Hall 10)
Date and Time: October 24, 2026, 8:30 AM – 10:00 AM CEST
About LYT-200
LYT-200 is a Phase 2-ready, fully human monoclonal antibody in development for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS). It is the most advanced therapeutic candidate targeting galectin-9, which is an important oncogenic driver and potent immunosuppressor that plays a central role in some of the most difficult-to-treat cancers. With its mutation-agnostic, dual mechanism of action, LYT-200 is designed to address both the malignant cells and the immunosuppressive environment that sustain disease. LYT-200 has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of R/R HR-MDS in combination with a hypomethylating agent. LYT-200 has also been granted Fast Track designation from the U.S. FDA for the treatment of acute myeloid leukemia (AML).
(Press release, PureTech Health, OCT 19, 2026, View Source [SID1234673594])